Research-Studien

26.11.21  DGAP-Research-Studien: 3U HOLDING AG
(von GSC Research GmbH): Halten
26.11.21  DGAP-Research-Studien: GK Software SE
(von Montega AG): Kaufen
25.11.21  DGAP-Research-Studien: Aroundtown SA
(von First Berlin Equity Research GmbH): Buy
25.11.21  DGAP-Research-Studien: asknet Solutions AG
(von Sphene Capital GmbH): Buy
24.11.21  DGAP-Research-Studien: GBC Insider Focus Index
(von GBC AG): GBC Insider Focus Index
24.11.21  DGAP-Research-Studien: Diversified Energy PLC
(von First Berlin Equity Research GmbH): Kaufen Diversified Energy PLC
24.11.21  DGAP-Research-Studien: MS Industrie AG
(von GBC AG): Kaufen
24.11.21  DGAP-Research-Studien: Netfonds AG
(von Montega AG): Kaufen
22.11.21  DGAP-Research-Studien: EQS Group AG
(von GBC AG): Kaufen
22.11.21  DGAP-Research-Studien: IGEA Pharma N.V.
(von GBC AG): BUY
22.11.21  DGAP-Research-Studien: German Real Estate Capital S.A.
(von GBC AG): Stark überdurchschnittlich attraktiv German Real Est [...]
22.11.21  DGAP-Research-Studien: USU Software AG
(von GBC AG): Kaufen
22.11.21  DGAP-Research-Studien: ad pepper media International N.V.
(von First Berlin Equity Research GmbH): Buy
22.11.21  DGAP-Research-Studien: Aspermont Limited
(von GBC AG): Kaufen Aspermont Limited
22.11.21  DGAP-Research-Studien: Aspermont Limited
(von GBC AG): BUY Aspermont Limited
19.11.21  DGAP-Research-Studien: ERWE Immobilien AG
(von GSC Research GmbH): Kaufen
19.11.21  DGAP-Research-Studien: Li-Metal Corp.
(von Sphene Capital GmbH): Buy
19.11.21  DGAP-Research-Studien: 2G Energy AG
(von First Berlin Equity Research GmbH): Hinzufügen
18.11.21  DGAP-Research-Studien: Media and Games Invest SE
(von First Berlin Equity Research GmbH): Buy
18.11.21  DGAP-Research-Studien: All for One Group SE
(von BankM AG): Kaufen

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021